Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Nuvectis Pharma (NVCT) will participate in the Maxim Growth Summit 2026 in New York on October 14, 2026.

Rhea-AI Summary

Nuvectis Pharma (NVCT) will participate in the Maxim Growth Summit 2026 in New York on October 14, 2026. Chairman and CEO Ron Bentsur will join the Immunology & Inflammation Therapies panel at 10:30 AM ET. A webcast of the panel discussion will be available in the Investors section of the company’s website.

Key Terms

complement factor b inhibitor, braf inhibitor, src family kinases

3 terms

complement factor b inhibitor medical

"a complement Factor B inhibitor in development for the treatment"

A complement factor B inhibitor is a drug designed to block a specific protein (factor B) in the body’s immune “alarm” system, preventing that system from overreacting and damaging healthy tissue. For investors it signals a targeted therapy approach with potentially clear clinical trial milestones, market opportunity in certain immune-driven diseases, and regulatory and reimbursement risks tied to safety, efficacy and competition—much like backing a precision tool that could replace a blunt instrument in treatment.

braf inhibitor medical

"an oral, brain-penetrant, paradox-breaker BRAF inhibitor"

A BRAF inhibitor is a type of drug that blocks the activity of the BRAF protein, which can drive uncontrolled cell growth when mutated in certain cancers. For investors, BRAF inhibitors matter because they are a targeted therapy class with regulatory pathways, clinical trial milestones, and market potential tied to specific tumor types and mutation tests; think of them as a precision switch that can stop a malfunctioning growth signal in tumors.

src family kinases medical

"inhibitor of the SRC family kinases, including SRC and YES1"

A group of closely related non-receptor tyrosine enzymes that add phosphate groups to tyrosine residues on proteins to control cell signaling. Src family kinases sit at the inner side of the cell membrane and help regulate processes such as cell growth, movement, adhesion and survival by turning signaling pathways on or off through phosphorylation; their activity is controlled by phosphorylation at specific sites and by interactions with other proteins. Because their switching changes how cells respond to external cues, abnormal activation or loss of control of these kinases is a common mechanism in diseases such as cancer and in some disorders of the immune and nervous systems.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Fort Lee, NJ, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.

Conference Details:

Panel Discussion:	Immunology & Inflammation Therapies
Presenter:	Ron Bentsur, Chairman and CEO
Date and Time:	Wednesday, October 14, 2026 at 10:30 AM ET
Webcast link:	Panel Discussion

A webcast of the panel discussion will be available in the Investors section of Nuvectis’ website at www.nuvectis.com.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.

The company’s lead drug candidate is ciprocopan, a once-a-day Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors.

NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, with best-in-class potential.

NXP900 is an oral small molecule inhibitor of the SRC family kinases, including SRC and YES1.

Company Contact

Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com

Media Relations Contact

Kevin Gardner
LifeSci Advisorskgardner@lifesciadvisors.com